Thoughts anybody on FMI's recent IPO and the impact that FMI will have in this increasingly crowded space?
While GHDX is the clear leader in the specific genomic tests for breast, colon and prostate cancer - to guide treatment decisions, the new competitor on the block is FMI. Looks like they could eat GHDX's lunch.
I'm currently in a HOLD pattern with GHDX, but I'm aware that they could potentially lose their leadership position. Your thoughts, Terry?